Randomized, placebo controlled and double-blind trials of efficacy and safety of
adalimumab for treating ankylosing spondylitis: a meta-analysis.
Author(s): Wang H(1), Zuo D, Sun M, Hua Y, Cai Z.
Affiliation(s): Author information:
(1)Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai,
China.
Publication date & source: 2014, Int J Rheum Dis. , 17(2):142-8
Adalimumab is a fully human, anti-TNF monoclonal antibody of proven efficacy and
safety in the treatment of the signs, symptoms and functional disability of
ankylosing spondylitis (AS). A systematic review and meta-analysis was performed
to assess the efficacy and safety of adalimumab treatment, relative to a placebo,
in adult patients with AS. In the efficacy meta-analysis, significantly more
patients in the adalimumab group achieved Assessment in AS International Working
Group (ASAS)20 and Bath AS Disease Activity Index (BASDAI)50 compared with
patients in the placebo group. Patients in the adalimumab group also showed
significant improvement in BASDAI and health-related quality of life. With regard
to adverse events, any adverse events and injection-site reaction were
significantly higher in the adalimumab group compared with the control group.
This meta-analysis shows a higher efficacy of adalimumab relative to placebo, but
clinicians should be careful regarding adverse events in adalimumab-treated
patients.
|